Journal article
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
Abstract
A randomized trial has been performed in which women with axillary node-positive breast cancer were allocated to either a short intensive 12-week chemohormonal treatment consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and tamoxifen (CMFVP plus AT) or 36 weeks of CMFVP. The median follow-up is 37 months. Of the 222 women randomized to the 12-week …
Authors
Levine MN; Gent M; Hryniuk WM; Bramwell V; Abu-Zahra H; DePauw S; Arnold A; Findlay B; Levin L; Skillings J
Journal
Journal of Clinical Oncology, Vol. 8, No. 7, pp. 1217–1225
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
7 1990
DOI
10.1200/jco.1990.8.7.1217
ISSN
0732-183X